Randomized, double-blind, placebo-controlled pilot clinical study, to investigate evolution in digestive symptoms in subjects with Proton Pump Inhibitors induced dysbiosis with or without concomitant use of Enterogermina® (Bacillus Clausii)
Condition studied
Dysbiosis
Investigational medicinal product(s)
Eligibility
Primary endpoint
Changes in the symptom score (GIQLI) from baseline to day 28 in patients treated with Enterogermina® compared to placebo
Endpoint detail
Changes in the symptom score (GIQLI) from baseline to day 14, day 35 and day 49 in patients treated with Enterogermina® compared to placebo, Changes in physical functioning, emotional well-being, social functioning, effects of medical treatment and the total GIQLI) from baseline to day 14, day 28, day 35 and day 49 in patients treated with Enterogermina® compared to placebo, Alpha diversity, beta diversity and taxonomic composition of the gut microbiome, measured by 16S rRNA sequencing in saliva, duodenal fluid and faeces at baseline, day 7, day 28 and day 42, Predicted function of the gut microbiome in saliva, duodenal fluid and faeces at baseline, day 7, day 28 and day 42, Changes in faecal zonulin and serum diamine oxidase from baseline to day 28 and day 42 in patients treated with Enterogermina® compared to placebo, Changes in faecal calprotectin, serum lipopolysaccharide binding protein, sCD14, c-reactive protein and ferritin from baseline to day 28 and day 42 in patients treated with Enterogermina® compared to placebo, Changes in NMR metabolomics profiling and functional prediction from serum and faeces from baseline to day 28 and day 42 in patients treated with Enterogermina® compared to placebo, Changes in Vitamin B12 levels from baseline to day 28 and day 42 in patients treated with Enterogermina® compared to placebo, Absolute and relative abundance for Bacillus clausii (O/C, N/R, SIN, and T) at baseline, day 7, day 28 and day 42 using targeted qPCR, Adverse events description.
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View 2026-527670-36-00 on CTIS ↗ ← All trials in the EU